Spinal Cord Injuries
Neurology·MeSH: Spinal Cord Injuries
Prevalence
30.0 / 100K
4 drugs in development·4 companies·25 clinical trials
Drug Pipeline by Phase
Approved(2)
Phase 1(1)
| Drug | Company |
|---|---|
| ast-opc1 | ASTERIAS BIOTHERAPEUTICS, INC. (AST) |
Phase 1/Phase 2(1)
| Drug | Company |
|---|---|
| nvg-291 | NERVGEN PHARMA CORP. (NGEN) |
Compare drugs
Frequently asked questions
How many drugs are in development for Spinal Cord Injuries?
BioSniper tracks 4 drugs in development for Spinal Cord Injuries across 4 companies.
How many clinical trials target Spinal Cord Injuries?
There are 25 clinical trials targeting Spinal Cord Injuries tracked by BioSniper.
What is the prevalence of Spinal Cord Injuries?
The estimated prevalence of Spinal Cord Injuries is approximately 30.0 per 100,000 population.
Deep-dive into Spinal Cord Injuries
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis